All In Biotech

Drug Trial Radar · NCT05341583

Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer

A Phase Ⅲ, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Ensartinib Versus Placebo as Adjuvant Therapy in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Stage IB- IIIB Non-small Cell Lung Cancer.

Last checked: Nov 20, 2026Latest source record: Aug 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 202 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

202

Planned (sponsor's estimate)

Start

May 24, 2022

Primary completion

Jun 1, 2025

Study completion Jul 23, 2025

Sponsor

Sponsor type
Industry
First posted
Apr 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This double-blind, randomized, placebo-controlled, multicenter, Phase III study is designed to evaluate the efficacy and safety of ensatinib compared with placebo as adjuvant treatment in ALK positive stage II-IIIB non-small cell lung cancer after surgical resection with or without chemotherapy.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • EnsartinibDrug

    Ensartinib 225 mg once daily until disease recurrence or up to 2 years, whichever occurs earlier.

  • PlaceboDrug

    Placebo 225 mg once daily until disease recurrence or up to 2 years, whichever occurs earlier.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease free survival (DFS)Time frame: up to 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • TianJin Medical University Cancer Institute & Hospital

    Tianjin, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.